[Studies on immunohistochemical localization and immunotargeting of monoclonal antibody against human hepatocellular carcinoma].
Human hepatocellular carcinoma (HCC) cell line SMMC-7721 treated with human leucocytic alpha-interferon was used as immunogen to prepare monoclonal antibody against HCC. The anti-HCC monoclonal antibody (HAb23) was used to reacte with 51 cases of HCC, 38 cases of cirrhosis, 33 cases of hepatitis, 25 cases of other liver diseases, 36 cases of normal tissues including cryosections of fetus tissues and 231 cases of malignacies from various tissues by immunohistochemical staining. The results showed that 42 cases of HCC were positive, with a positive rate of 82.3%. Immuno-electron microscopic localization showed that HAb23 was localized mainly on the surface membrane and on the cytoplasmic membranous structures of tumor cells. The radioiodine conjugated HAb23 could target to the xenografts shown by ECT scanning. The ratios of tumor/liver and tumor/blood were 1.94-3.66 and 0.56-1.65, respectively. Five nm colloidal gold labeled HAb23 could also target to the xenografts. Our data suggest that the HAb23 is more specific to HCC and has a targeting ability to HCC in vivo.